Camp4 Therapeutics (CAMP) Times Interest Earned (2023 - 2024)
Camp4 Therapeutics (CAMP) posted Times Interest Earned of -$233.41 for Q1 2026, down 4475.54% sequentially from $5.33 in Q4 2025, and down 1924.08% YoY from $12.8 in Q1 2025.
Analysis
Camp4 Therapeutics (CAMP) Times Interest Earned (2023 - 2024) Analysis & Trends
Camp4 Therapeutics has reported Times Interest Earned for 4 years, with the latest figure at -$233.41 in Q1 2026.
- Quarterly Times Interest Earned fell 1924.08% year-over-year to -$233.41 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.63 (up 220.22% YoY) and the FY2025 annual result came in at -$0.69, up 15.59% from the prior year.
- Times Interest Earned slipped to -$233.41 in Q1 2026 per CAMP's latest filing, from $5.33 in the prior quarter.
- Over five years, Times Interest Earned peaked at $5.64 in Q4 2024 and troughed at -$233.41 in Q1 2026.
- A 4-year average of -$42.04 and a median of -$11.67 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2024 and 2026: Times Interest Earned jumped 103.47% in 2024, then sank 1924.08% in 2026.
- Over 4 years, Times Interest Earned stood at -$162.36 in 2023, then soared by 103.47% to $5.64 in 2024, then decreased by 5.35% to $5.33 in 2025, then plunged by 4475.54% to -$233.41 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$233.41, $5.33, and -$15.58 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Camp4 Therapeutics | 260.10 Mn | 260.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 96.79 |
| Sep 30, 2024 | -218.00 |
| Dec 31, 2023 | -162.36 |
| Sep 30, 2023 | -262.51 |